{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T07:10:25Z","timestamp":1758265825815},"reference-count":64,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiology Clinics"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.ccl.2013.07.001","type":"journal-article","created":{"date-parts":[[2013,8,9]],"date-time":"2013-08-09T22:54:49Z","timestamp":1376088889000},"page":"533-544","source":"Crossref","is-referenced-by-count":6,"title":["Novel Antiplatelet and Anticoagulant Agents in the Cardiac Care Unit"],"prefix":"10.1016","volume":"31","author":[{"given":"Vaani Panse","family":"Garg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan L.","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ccl.2013.07.001_bib1","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1161\/CIRCULATIONAHA.109.192667","article-title":"Heart disease and stroke statistics\u20142010 update: a report from the American Heart Association","volume":"121","author":"Writing Group Members","year":"2010","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ccl.2013.07.001_bib2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/CIRCULATIONAHA.109.853085","article-title":"Combination antithrombotic therapies","volume":"121","author":"Gurbel","year":"2010","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.ccl.2013.07.001_bib3","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1161\/CIR.0b013e318212bb8b","volume":"123","author":"Anderson","year":"2011","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ccl.2013.07.001_bib4","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jacc.2012.06.004","volume":"60","author":"Jneid","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"Suppl 2","key":"10.1016\/j.ccl.2013.07.001_bib5","doi-asserted-by":"crossref","first-page":"53S","DOI":"10.1378\/chest.11-2288","article-title":"Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Guyatt","year":"2012","journal-title":"Chest"},{"issue":"20","key":"10.1016\/j.ccl.2013.07.001_bib6","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ccl.2013.07.001_bib7","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ccl.2013.07.001_bib8","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.ccl.2013.07.001_bib9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.ccl.2013.07.001_bib10","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"EINSTEIN Investigators","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ccl.2013.07.001_bib11","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ccl.2013.07.001_bib12","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1056\/NEJM198308183090703","article-title":"Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative study","volume":"309","author":"Lewis","year":"1983","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.ccl.2013.07.001_bib13","doi-asserted-by":"crossref","first-page":"321S","DOI":"10.1378\/chest.119.1_suppl.321S","article-title":"Antithrombotic therapy in patients undergoing percutaneous coronary intervention","volume":"119","author":"Popma","year":"2001","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.ccl.2013.07.001_bib14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1161\/01.CIR.76.1.125","article-title":"Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty","volume":"76","author":"Barnathan","year":"1987","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.ccl.2013.07.001_bib15","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM198810273191701","article-title":"Aspirin, heparin, or both to treat acute unstable angina","volume":"319","author":"Theroux","year":"1988","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ccl.2013.07.001_bib16","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.ccl.2013.07.001_bib17","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"J\u00a0Am Med Assoc"},{"issue":"12","key":"10.1016\/j.ccl.2013.07.001_bib18","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"9497","key":"10.1016\/j.ccl.2013.07.001_bib19","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2013.07.001_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/VHRM.S26030","article-title":"Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options","volume":"8","author":"Fintel","year":"2012","journal-title":"Vasc Health Risk Manag"},{"issue":"1","key":"10.1016\/j.ccl.2013.07.001_bib21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11883-011-0216-x","article-title":"Novel antiplatelet therapies","volume":"14","author":"Kim","year":"2012","journal-title":"Curr Atheroscler Rep"},{"issue":"23","key":"10.1016\/j.ccl.2013.07.001_bib22","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel\u00a0for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ccl.2013.07.001_bib23","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jacc.2004.09.067","article-title":"Variability in platelet responsiveness to clopidogrel among 544 individuals","volume":"45","author":"Serebruany","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.ccl.2013.07.001_bib24","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/eurheartj\/ehi877","article-title":"Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease","volume":"27","author":"Jernberg","year":"2006","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.ccl.2013.07.001_bib25","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","volume":"116","author":"Wiviott","year":"2007","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.ccl.2013.07.001_bib26","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.ccl.2013.07.001_bib27","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jacc.2007.07.053","volume":"50","author":"Cannon","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.ccl.2013.07.001_bib28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"A\u00a0comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group","volume":"337","author":"Cohen","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.ccl.2013.07.001_bib29","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.ccl.2013.07.001_bib30","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJMoa011258","article-title":"A\u00a0comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke","volume":"345","author":"Mohr","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.ccl.2013.07.001_bib31","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa035029","article-title":"Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism","volume":"348","author":"Ridker","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ccl.2013.07.001_bib32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1161\/CIRCOUTCOMES.110.957738","article-title":"Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs study to improve anticoagulation (VARIA)","volume":"4","author":"Rose","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"5","key":"10.1016\/j.ccl.2013.07.001_bib33","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/0091270005274550","article-title":"Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement","volume":"45","author":"Stangier","year":"2005","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.ccl.2013.07.001_bib34","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.ahj.2012.03.011","article-title":"A\u00a0comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN)","volume":"163","author":"Van de Werf","year":"2012","journal-title":"Am Heart J"},{"issue":"15","key":"10.1016\/j.ccl.2013.07.001_bib35","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.2165\/11641160-000000000-00000","article-title":"Management of bleeding in patients receiving conventional or new anticoagulants: a practical and case-based approach","volume":"72","author":"Donadini","year":"2012","journal-title":"Drugs"},{"issue":"24","key":"10.1016\/j.ccl.2013.07.001_bib36","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ccl.2013.07.001_bib37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40262-012-0030-9","article-title":"New oral anticoagulants: comparative pharmacology with vitamin K antagonists","volume":"52","author":"Scaglione","year":"2013","journal-title":"Clin Pharm"},{"issue":"5","key":"10.1016\/j.ccl.2013.07.001_bib38","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","article-title":"Ticagrelor compared with clopidogrel by geographic region in the platelet inhibition and patient outcomes (PLATO) trial","volume":"124","author":"Mahaffey","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2013.07.001_bib39","doi-asserted-by":"crossref","first-page":"d3527","DOI":"10.1136\/bmj.d3527","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised platelet inhibition and patient outcomes (PLATO) trial","volume":"342","author":"James","year":"2011","journal-title":"BMJ"},{"issue":"14","key":"10.1016\/j.ccl.2013.07.001_bib40","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.ccl.2013.07.001_bib41","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.ccl.2013.07.001_bib42","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"9683","key":"10.1016\/j.ccl.2013.07.001_bib43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ccl.2013.07.001_bib44","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ccl.2013.07.001_bib45","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ahj.2010.06.042","volume":"160","author":"Ruff","year":"2010","journal-title":"Am Heart J"},{"issue":"10","key":"10.1016\/j.ccl.2013.07.001_bib46","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1161\/CIR.0b013e31820f14c0","article-title":"2011 ACCF\/AHA\/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines","volume":"123","author":"Wann","year":"2011","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.ccl.2013.07.001_bib47","first-page":"401","article-title":"Venous thromboembolism in adult hospitalizations - United States, 2007-2009","volume":"61","author":"Centers for Disease Control and Prevention (CDC)","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.ccl.2013.07.001_bib48","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ccm.2008.11.003","article-title":"Coagulation disorders in the ICU","volume":"30","author":"Marks","year":"2009","journal-title":"Clin Chest Med"},{"issue":"2","key":"10.1016\/j.ccl.2013.07.001_bib49","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jcrc.2009.03.004","article-title":"Management of venous thromboembolism in the intensive care unit","volume":"24","author":"Pastores","year":"2009","journal-title":"J\u00a0Crit Care"},{"issue":"3","key":"10.1016\/j.ccl.2013.07.001_bib50","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccc.2012.04.005","article-title":"Newer anticoagulants in critically ill patients","volume":"28","author":"Rajasekhar","year":"2012","journal-title":"Crit Care Clin"},{"issue":"8","key":"10.1016\/j.ccl.2013.07.001_bib51","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.ccl.2013.07.001_bib52","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"EINSTEIN-PE Investigators","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ccl.2013.07.001_bib53","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1111096","article-title":"Rivaroxaban for thromboprophylaxis in acutely ill medical patients","volume":"368","author":"Cohen","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ccl.2013.07.001_bib54","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1302\/0301-620X.91B5.21691","article-title":"Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement","volume":"91","author":"Eriksson","year":"2009","journal-title":"J\u00a0Bone Joint Surg Br"},{"issue":"Suppl 6","key":"10.1016\/j.ccl.2013.07.001_bib55","doi-asserted-by":"crossref","first-page":"110S","DOI":"10.1378\/chest.08-0652","article-title":"Antithrombotic and thrombolytic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)","volume":"133","author":"Hirsh","year":"2008","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.ccl.2013.07.001_bib56","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1097\/ALN.0b013e318289bcba","article-title":"Managing new oral anticoagulants in the perioperative and intensive care unit setting","volume":"118","author":"Levy","year":"2013","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ccl.2013.07.001_bib57","doi-asserted-by":"crossref","unstructured":"van Ryn J, Litzenberger T, Gan G, et\u00a0al. In\u00a0vitro characterization, pharmacokinetics and reversal of supratherapeutic doses of dabigatran-induced bleeding in rats by a specific antibody fragment antidote to dabigatran [abstract]. Presented at the 54th ASH Annual Meeting and Exposition. Atlanta, December 8\u201310, 2012. Abstract 3418.","DOI":"10.1182\/blood.V120.21.3418.3418"},{"key":"10.1016\/j.ccl.2013.07.001_bib58","doi-asserted-by":"crossref","unstructured":"Toth J, van Ryn J, Dursema H, et\u00a0al. Reversal of dabigatran\u2019s anticoagulant activity in the monkey by a specific antidote and pharmacokinetic and pharmacodynamic modeling [abstract]. Presented at the 54th ASH Annual Meeting and Exposition. Atlanta, December 8\u201310, 2012. Abstract 22.","DOI":"10.1182\/blood.V120.21.22.22"},{"key":"10.1016\/j.ccl.2013.07.001_bib59","doi-asserted-by":"crossref","unstructured":"Lu G, DeGuzman FR, Lakhotia S, et\u00a0al. Recombinant antidote for reversal of anticoagulation by factor Xa inhibitors [abstract]. Presented at the 50th ASH Annual Meeting and Exposition. San Francisco, December 6\u20139, 2008. Abstract 983.","DOI":"10.1182\/blood.V112.11.983.983"},{"key":"10.1016\/j.ccl.2013.07.001_bib60","first-page":"309","article-title":"Reconstructed recombinant factor Xa as an antidote to reverse anticoagulation by factor Xa inhibitors","volume":"7","author":"Lu","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ccl.2013.07.001_bib61","doi-asserted-by":"crossref","unstructured":"Hollenbach SJ, Lu G, Tan S, et\u00a0al. PRT064445 but not recombinant FVIIa reverses rivaroxaban induced anticoagulation as measured by reduction in blood loss in a rabbit liver laceration model [abstract]. Presented at the 54th ASH Annual Meeting and Exposition. Atlanta, December 8\u201310, 2012. Abstract 3414.","DOI":"10.1182\/blood.V120.21.3414.3414"},{"key":"10.1016\/j.ccl.2013.07.001_bib62","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/j.1538-7836.2005.01374.x","article-title":"New anticoagulants","volume":"3","author":"Weitz","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ccl.2013.07.001_bib63","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/eurheartj\/ehm575","article-title":"New oral anticoagulants in atrial fibrillation","volume":"29","author":"Turpie","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ccl.2013.07.001_bib64","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.2174\/092986707782023659","article-title":"The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development","volume":"14","author":"Geurtin","year":"2007","journal-title":"Curr Med Chem"}],"container-title":["Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865113000647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865113000647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T19:32:45Z","timestamp":1596310365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733865113000647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0733865113000647"],"URL":"https:\/\/doi.org\/10.1016\/j.ccl.2013.07.001","relation":{},"ISSN":["0733-8651"],"issn-type":[{"value":"0733-8651","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}